Vitiligo's clinical course splits into segmental and non-segmental presentations, each carrying a distinct prognosis. Dr. Rosmarin explains how disease activity, not just extent, determines whether a patient needs urgent intervention or watchful monitoring.
Body surface area offers a simple starting point for gauging vitiligo severity, but the panel argues that phenotype markers, anatomic location, and disease activity carry more weight in shaping treatment urgency than surface area alone.
Halting progression early is more achievable than reversing it. Dr. Rosmarin details how oral steroids control active disease while payer barriers persist for later-line options, and Jason explains how benefit design and step therapy shape access.
A recent JAMA Dermatology analysis refines mild-moderate-severe cutoffs for vitiligo, but Dr. Desai and Dr. Lal argue that psychosocial burden, anatomic site, and cultural context can make even limited disease profoundly severe for patients.
From corticosteroids and calcineurin inhibitors to phototherapy, oral supplements, and emerging JAK inhibitors, Dr. Rosmarin walks through a treatment landscape defined by combination therapy rather than any single modality working alone.
JAK inhibitors mark a genuine shift in vitiligo care, offering stabilization before repigmentation and color that matches native skin tone. Dr. Desai and Dr. Lal weigh their promise against the patience and compliance they demand.
